Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects

Enzo Emanuele, Emmanouil Peros, Piercarlo Minoretti, Colomba Falcone, Angela D'Angelo, Lorenza Montagna, Diego Geroldi

Research output: Contribution to journalArticle

Abstract

Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus 40.8%, P <0.05) and with respect to the control group (55.5% versus 39.8%, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.

Original languageEnglish
Article number12
JournalBMC Cardiovascular Disorders
Volume3
DOIs
Publication statusPublished - Dec 12 2003

Fingerprint

Apoprotein(a)
Coronary Disease
Lipoprotein(a)
Protein Isoforms
Phenotype
Weights and Measures
Immunoblotting
Biomarkers
Molecular Weight
Enzyme-Linked Immunosorbent Assay
Regression Analysis
Control Groups

Keywords

  • Apolipoprotein(a) isoforms
  • Coronary heart disease
  • Genetic markers
  • Lipoprotein(a) concentration
  • Overweight

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects. / Emanuele, Enzo; Peros, Emmanouil; Minoretti, Piercarlo; Falcone, Colomba; D'Angelo, Angela; Montagna, Lorenza; Geroldi, Diego.

In: BMC Cardiovascular Disorders, Vol. 3, 12, 12.12.2003.

Research output: Contribution to journalArticle

Emanuele, Enzo ; Peros, Emmanouil ; Minoretti, Piercarlo ; Falcone, Colomba ; D'Angelo, Angela ; Montagna, Lorenza ; Geroldi, Diego. / Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects. In: BMC Cardiovascular Disorders. 2003 ; Vol. 3.
@article{59a2a547669f4699820e95b5d3c0b002,
title = "Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects",
abstract = "Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5{\%} versus 40.8{\%}, P <0.05) and with respect to the control group (55.5{\%} versus 39.8{\%}, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.",
keywords = "Apolipoprotein(a) isoforms, Coronary heart disease, Genetic markers, Lipoprotein(a) concentration, Overweight",
author = "Enzo Emanuele and Emmanouil Peros and Piercarlo Minoretti and Colomba Falcone and Angela D'Angelo and Lorenza Montagna and Diego Geroldi",
year = "2003",
month = "12",
day = "12",
doi = "10.1186/1471-2261-3-12",
language = "English",
volume = "3",
journal = "BMC Cardiovascular Disorders",
issn = "1471-2261",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Relationship between apolipoprotein(a) size plymorphism and coronary heart disease in overweight subjects

AU - Emanuele, Enzo

AU - Peros, Emmanouil

AU - Minoretti, Piercarlo

AU - Falcone, Colomba

AU - D'Angelo, Angela

AU - Montagna, Lorenza

AU - Geroldi, Diego

PY - 2003/12/12

Y1 - 2003/12/12

N2 - Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus 40.8%, P <0.05) and with respect to the control group (55.5% versus 39.8%, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.

AB - Background: Overweight is associated with an increased cardiovascular risk which is only partially explained by conventional risk factors. The objective of this study was to evaluate lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to coronary heart disease (CHD) in overweight subjects. Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a) isoforms were detected by a high-resolution immunoblotting method. Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5-50.3) versus 12.6 (2.6-38.6) mg/dl, P <0.05]. Furthermore, overweight subjects with CHD showed a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus 40.8%, P <0.05) and with respect to the control group (55.5% versus 39.8%, P <0.05). Stepwise regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as significant independent predictors of CHD in overweight subjects. Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive treatment of modifiable cardiovascular risk factors.

KW - Apolipoprotein(a) isoforms

KW - Coronary heart disease

KW - Genetic markers

KW - Lipoprotein(a) concentration

KW - Overweight

UR - http://www.scopus.com/inward/record.url?scp=3042588235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042588235&partnerID=8YFLogxK

U2 - 10.1186/1471-2261-3-12

DO - 10.1186/1471-2261-3-12

M3 - Article

C2 - 14670093

AN - SCOPUS:3042588235

VL - 3

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

SN - 1471-2261

M1 - 12

ER -